SCHEMBL3981492

SCHEMBL3981492

Cc1nn(Cc2ccc(Cl)c(Cl)c2)c(=O)c2c(O)c3n(c12)CCN(C)C3=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.40
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
PTGDR2 Q9Y5Y4 3/20 0.38
SMN1; SMN2 Q16637 7/20 0.37
LMNA P02545 4/20 0.37
HTT P42858 3/20 0.37
ALDH1A1 P00352 2/20 0.37
TSHR P16473 2/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
ADORA3 P0DMS8 1/20 0.36
LIPG Q9Y5X9 3/20 0.36
TP53 P04637 2/20 0.35
GAA P10253 1/20 0.35
CYP2C9 P11712 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
UBE2N P61088 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3986662 0.90 GAA (0.38) SMN1; SMN2LMNAHTTALDH1A1TSHR
SCHEMBL3985863 0.89 PKM (0.35) SMN1; SMN2LMNAHTTALDH1A1TSHR
SCHEMBL3985002 0.88 NPBWR1 (0.35) ADORA1LMNAPOLBTP53PPARG
SCHEMBL3989304 0.88 LMNA (0.41) MAOBADORA2ASMN1; SMN2LMNAHTT
SCHEMBL3983532 0.87 PKM (0.44) HTTALDH1A1TSHRMAPTTP53
SCHEMBL3985461 0.87 PDE5A (0.39) ADORA1POLBMAPTGAA
SCHEMBL3985346 0.86 PKM (0.36) MAOBHTTALDH1A1POLB
SCHEMBL3985745 0.86 NPBWR1 (0.37) PTGDR2SMN1; SMN2LMNAALDH1A1POLB
SCHEMBL3992564 0.85 PDE5A (0.38) MAOBSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL3985716 0.84 PDE5A (0.46) SMN1; SMN2LMNAHTTALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US claimed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US claimed
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
EP-1756114-A2 HIV INTEGRASE INHIBITORS Merck and Co., Inc. (US) 2007-02-28 EP disclosed
WO-2005110414-A2 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-11-24 WO disclosed
WO-2005110415-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287394-A1 Hiv Integrase Inhibitors DHPS, DPYD, TYMP MAOB 2049/4885ADORA2A 1987/4885ADORA1 1235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.